Raising capital for an early-stage MedTech company has never been more complex – or more full of opportunity.

With shifting macroeconomic conditions, increasingly
sophisticated angel investors, and higher expectations around financial modeling and
governance, founders must be sharper, faster, and far more capital-efficient than in
previous cycles.

Yet for those who execute well, there is substantial capital ready to be deployed.

Capital Efficiency Is the Name of the Game

In today’s environment, investors care less about how much you raise and far more about
what you can accomplish with each dollar. MedTech, by its nature, carries regulatory and
technical hurdles, but founders who demonstrate a lean, milestone-oriented deployment of
capital stand out immediately.

Capital efficiency isn’t about austerity – it’s about clarity. Investors want to see logical
sequencing of spending, crisp gating milestones, and a disciplined approach that proves you
understand not only how to build the technology but also how to build the business.

Founders who can articulate how a seed round translates into clinical feasibility, regulatory
de-risking, or data that meaningfully advances valuation will always have the edge.

High-Net-Worth Investors Are Looking Beyond Public Markets

With persistent concerns about a looming correction in public equities, more high-net-
worth individuals are moving upstream into private markets – especially MedTech, where
tangible products, strong clinical need, and clear regulatory pathways can create
compelling, non-correlated returns.

These investors are increasingly willing to back early-stage founders, but they expect
institutional-grade thinking. They want to understand:

• How their capital compounds over time
• Where value inflection points sit
• How downside protection and upside participation are structured

This new wave of sophisticated angels and family offices is no longer satisfied with a
handshake and a pitch deck – they expect models, structure, and transparency.

Schmooze Locally: Proximity Still Matters

Despite the global reach of capital, early-stage fundraising remains deeply relationship-
driven. Some of the most durable capital partners come from local networks – clinicians,
exited founders, MedTech executives, and regional angel groups who understand the
ecosystem and are often willing to be more patient and supportive than institutional
investors.

Attend local events. Speak on panels. Get to know the physicians and hospital
administrators who may one day become your advisors, advocates, or investors. Warm
introductions from trusted community members still outperform cold outreach by an order
of magnitude.

MedTech is a small world; build your reputation early.

The Rise of the Sophisticated Seed: Why the ROI Waterfall–Valuation Relationship Matters

One of the most notable shifts in early-stage fundraising is the growing sophistication of
both founders and investors. Seed-stage companies are now expected to present equity

structures, financial models, and scenario analyses that were once reserved for Series A or
later.

At the center of this shift is the ROI waterfall – not as a standalone artifact, but as a bridge
between valuation, dilution, and exit reality.

A well-constructed ROI waterfall does more than show returns at exit. It provides critical
insight into whether a company’s current valuation makes sense in the context of plausible
future outcomes. Rather than anchoring valuation to what founders hope the company
might be worth someday, the conversation shifts to how different exit scenarios – ranging
from downside to base case to outlier success – translate into investor outcomes after
future dilution.

This framing makes ROI sensitivity far more meaningful. Investors can see how entry price,
follow-on capital needs, and ownership evolution interact across outcomes. In turn,
founders gain a clearer understanding of where their valuation likely needs to land today in
order to support attractive risk-adjusted returns tomorrow.

If this seems advanced, it is – plenty of exited companies have never had to create such
sophisticated forward-looking models, and advisors may hold the outdated opinion that a
great idea and passion are enough to raise a seed round. But as exits have become harder to
come by, the weed-out phase for MedTech startups has moved earlier in the company
lifecycle.

The ROI waterfall ties strategy, capital planning, and valuation together into a coherent
narrative that resonates with all investors and requires experience guiding companies from
founding to exit.

When done well, the ROI waterfall transforms an uncertain future into a transparent set of
trade-offs – building confidence, accelerating diligence, and reducing friction during
negotiation.

At Three Bridges, we specialize in building ROI waterfalls for early-stage MedTech startups
with exactly this purpose in mind. Drawing on our experience as both investors and

operators in the MedTech space, we design models that reflect the realities of regulatory
pathways, hardware development timelines, reimbursement dynamics, and real-world
dilution. The result is not just a cleaner model – but a sharper fundraising story that helps
founders raise more efficiently, negotiate from a position of strength, and retain ownership
over time.

Final Thoughts

Fundraising in MedTech is evolving. Capital efficiency, investor sophistication, and the
power of local relationships all play a central role. As more high-net-worth individuals seek
opportunities outside public markets, early-stage MedTech startups with the right
narrative, the right structure, and the right financial frameworks have a distinct advantage.

Tools like the ROI waterfall – once viewed as a “nice-to-have” – are increasingly becoming
signals of a founder who is prepared, credible, and serious about building a durable
company.

For your convenience, we’ve included a basic ROI waterfall spreadsheet template to help
you begin framing this conversation with investors.